Business Description
IGC Pharma Inc
NAICS : 541714
SIC : 2834
ISIN : US45408X3089
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.66 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -9.34 | |||||
Beneish M-Score | -5.1 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45.1 | |||||
3-Year EBITDA Growth Rate | -7 | |||||
3-Year EPS without NRI Growth Rate | -9 | |||||
3-Year FCF Growth Rate | 24 | |||||
3-Year Book Growth Rate | -25.3 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 37.77 | |||||
9-Day RSI | 43.75 | |||||
14-Day RSI | 47.55 | |||||
6-1 Month Momentum % | 14.18 | |||||
12-1 Month Momentum % | 5.52 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.85 | |||||
Quick Ratio | 0.86 | |||||
Cash Ratio | 0.71 | |||||
Days Inventory | 1679.99 | |||||
Days Sales Outstanding | 48.75 | |||||
Days Payable | 353.88 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.5 | |||||
Shareholder Yield % | -9.04 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 51.4 | |||||
Operating Margin % | -959.46 | |||||
Net Margin % | -1163.24 | |||||
FCF Margin % | -539.31 | |||||
ROE % | -101.64 | |||||
ROA % | -87.65 | |||||
ROIC % | -92.62 | |||||
ROC (Joel Greenblatt) % | -126.36 | |||||
ROCE % | -81.86 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 21.74 | |||||
PB Ratio | 3.22 | |||||
Price-to-Tangible-Book | 3.71 | |||||
EV-to-EBIT | -2.53 | |||||
EV-to-EBITDA | -2.67 | |||||
EV-to-Revenue | 24.26 | |||||
EV-to-Forward-Revenue | 21.09 | |||||
EV-to-FCF | -4.5 | |||||
Price-to-Median-PS-Value | 2.27 | |||||
Price-to-Net-Current-Asset-Value | 20.4 | |||||
Earnings Yield (Greenblatt) % | -39.53 | |||||
FCF Yield % | -21.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
IGC Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.127 | ||
EPS (TTM) (€) | -0.242 | ||
Beta | 0.67 | ||
Volatility % | 39.35 | ||
14-Day RSI | 47.55 | ||
14-Day ATR (€) | 0.042791 | ||
20-Day SMA (€) | 0.4773 | ||
12-1 Month Momentum % | 5.52 | ||
52-Week Range (€) | 0.236 - 0.69 | ||
Shares Outstanding (Mil) | 66.81 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
IGC Pharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
IGC Pharma Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
IGC Pharma Inc Frequently Asked Questions
What is IGC Pharma Inc(FRA:IGS1)'s stock price today?
When is next earnings date of IGC Pharma Inc(FRA:IGS1)?
Does IGC Pharma Inc(FRA:IGS1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |